These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 19325136)

  • 1. The type III transforming growth factor-beta receptor negatively regulates nuclear factor kappa B signaling through its interaction with beta-arrestin2.
    You HJ; How T; Blobe GC
    Carcinogenesis; 2009 Aug; 30(8):1281-7. PubMed ID: 19325136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TβRIII/β-arrestin2 regulates integrin α5β1 trafficking, function, and localization in epithelial cells.
    Mythreye K; Knelson EH; Gatza CE; Gatza ML; Blobe GC
    Oncogene; 2013 Mar; 32(11):1416-27. PubMed ID: 22562249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The transforming growth factor-beta type III receptor mediates distinct subcellular trafficking and downstream signaling of activin-like kinase (ALK)3 and ALK6 receptors.
    Lee NY; Kirkbride KC; Sheu RD; Blobe GC
    Mol Biol Cell; 2009 Oct; 20(20):4362-70. PubMed ID: 19726563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The type III TGF-beta receptor regulates epithelial and cancer cell migration through beta-arrestin2-mediated activation of Cdc42.
    Mythreye K; Blobe GC
    Proc Natl Acad Sci U S A; 2009 May; 106(20):8221-6. PubMed ID: 19416857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knockdown of the transforming growth factor-beta type III receptor impairs motility and invasion of metastatic cancer cells.
    Criswell TL; Dumont N; Barnett JV; Arteaga CL
    Cancer Res; 2008 Sep; 68(18):7304-12. PubMed ID: 18794117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The balance of cell surface and soluble type III TGF-β receptor regulates BMP signaling in normal and cancerous mammary epithelial cells.
    Gatza CE; Elderbroom JL; Oh SY; Starr MD; Nixon AB; Blobe GC
    Neoplasia; 2014 Jun; 16(6):489-500. PubMed ID: 25077702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type III TGF-β receptor inhibits cell proliferation and migration in salivary glands adenoid cystic carcinoma by suppressing NF-κB signaling.
    Xu D; Li D; Lu Z; Dong X; Wang X
    Oncol Rep; 2016 Jan; 35(1):267-74. PubMed ID: 26531330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the type III TGF-beta receptor is negatively regulated by TGF-beta.
    Hempel N; How T; Cooper SJ; Green TR; Dong M; Copland JA; Wood CG; Blobe GC
    Carcinogenesis; 2008 May; 29(5):905-12. PubMed ID: 18299279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The interaction of endoglin with beta-arrestin2 regulates transforming growth factor-beta-mediated ERK activation and migration in endothelial cells.
    Lee NY; Blobe GC
    J Biol Chem; 2007 Jul; 282(29):21507-17. PubMed ID: 17540773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta-arrestin 2 mediates endocytosis of type III TGF-beta receptor and down-regulation of its signaling.
    Chen W; Kirkbride KC; How T; Nelson CD; Mo J; Frederick JP; Wang XF; Lefkowitz RJ; Blobe GC
    Science; 2003 Sep; 301(5638):1394-7. PubMed ID: 12958365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type III TGF-β receptor enhances colon cancer cell migration and anchorage-independent growth.
    Gatza CE; Holtzhausen A; Kirkbride KC; Morton A; Gatza ML; Datto MB; Blobe GC
    Neoplasia; 2011 Aug; 13(8):758-70. PubMed ID: 21847367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ectodomain shedding of TβRIII is required for TβRIII-mediated suppression of TGF-β signaling and breast cancer migration and invasion.
    Elderbroom JL; Huang JJ; Gatza CE; Chen J; How T; Starr M; Nixon AB; Blobe GC
    Mol Biol Cell; 2014 Aug; 25(16):2320-32. PubMed ID: 24966170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The type III TGF-beta receptor signals through both Smad3 and the p38 MAP kinase pathways to contribute to inhibition of cell proliferation.
    You HJ; Bruinsma MW; How T; Ostrander JH; Blobe GC
    Carcinogenesis; 2007 Dec; 28(12):2491-500. PubMed ID: 17768179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The type III TGF-beta receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-beta signaling.
    Lee JD; Hempel N; Lee NY; Blobe GC
    Carcinogenesis; 2010 Feb; 31(2):175-83. PubMed ID: 19955393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer.
    Jovanović B; Beeler JS; Pickup MW; Chytil A; Gorska AE; Ashby WJ; Lehmann BD; Zijlstra A; Pietenpol JA; Moses HL
    Breast Cancer Res; 2014 Jul; 16(4):R69. PubMed ID: 24985072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma.
    Cooper SJ; Zou H; Legrand SN; Marlow LA; von Roemeling CA; Radisky DC; Wu KJ; Hempel N; Margulis V; Tun HW; Blobe GC; Wood CG; Copland JA
    Oncogene; 2010 May; 29(20):2905-15. PubMed ID: 20208565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased expression of the type III TGF-β receptor enhances metastasis and invasion in hepatocellullar carcinoma progression.
    Zhang S; Sun WY; Wu JJ; Gu YJ; Wei W
    Oncol Rep; 2016 Apr; 35(4):2373-81. PubMed ID: 26882862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of NFkappaB activity and E-cadherin by the type III transforming growth factor beta receptor regulates cell growth and motility.
    Criswell TL; Arteaga CL
    J Biol Chem; 2007 Nov; 282(44):32491-500. PubMed ID: 17823118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TβRIII independently binds type I and type II TGF-β receptors to inhibit TGF-β signaling.
    Tazat K; Hector-Greene M; Blobe GC; Henis YI
    Mol Biol Cell; 2015 Oct; 26(19):3535-45. PubMed ID: 26269580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic Ki-ras confers a more aggressive colon cancer phenotype through modification of transforming growth factor-beta receptor III.
    Yan Z; Deng X; Friedman E
    J Biol Chem; 2001 Jan; 276(2):1555-63. PubMed ID: 11029459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.